<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03187496</url>
  </required_header>
  <id_info>
    <org_study_id>EDP 305-004</org_study_id>
    <nct_id>NCT03187496</nct_id>
  </id_info>
  <brief_title>Drug-drug Interaction Study Between EDP-305, Midazolam, Caffeine and Rosuvastatin in Healthy Volunteers.</brief_title>
  <official_title>A Non-Randomized, Multiple-Dose, Open-Label, Single Sequence Study to Evaluate the Effect of Concomitant Administration of EDP-305 on the Pharmacokinetics and Safety of Midazolam, Caffeine, and Rosuvastatin in Healthy Human Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Enanta Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Enanta Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A non-randomized, multiple-dose, open-label, single sequence study to evaluate effect of
      concomitant administration of EDP-305 on the pharmacokinetics and safety of midazolam,
      caffeine, and rosuvastatin in healthy human volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 11, 2017</start_date>
  <completion_date type="Actual">June 14, 2017</completion_date>
  <primary_completion_date type="Actual">June 1, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of midazolam, caffeine, and rosuvastatin with and without the coadministration of EDP-305.</measure>
    <time_frame>Up to 17 Days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC of midazolam, caffeine, and rosuvastatin with and without the coadministration of EDP-305.</measure>
    <time_frame>Up to 17 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax of 1'-hydroxymidazolam, paraxanthine and N-desmethyl-rosuvastatin with and without the coadministration of EDP-305.</measure>
    <time_frame>Up to 17 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of 1'-hydroxymidazolam, paraxanthine and N-desmethyl-rosuvastatin with and without the coadministration of EDP-305.</measure>
    <time_frame>Up to 17 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of midazolam, 1'-hydroxymidazolam, caffeine, paraxanthine, rosuvastatin and N-desmethyl-rosuvastatin with and without the coadministration of EDP-305.</measure>
    <time_frame>Up to 17 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of midazolam, 1'-hydroxymidazolam, caffeine, paraxanthine, rosuvastatin and N-desmethyl-rosuvastatin with and without the coadministration of EDP-305.</measure>
    <time_frame>Up to 17 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of midazolam, caffeine and rosuvastatin with and without the coadministration of EDP-305.</measure>
    <time_frame>Up to 17 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F of midazolam, 1'-hydroxymidazolam, caffeine, paraxanthine, rosuvastatin and N-desmethyl-rosuvastatin with and without the coadministration of EDP-305.</measure>
    <time_frame>Up to 17 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC ratios for 1'-hydroxymidazolam/midazolam, paraxanthine/caffeine, and N-desmethyl-rosuvastatin/rosuvastatin.</measure>
    <time_frame>Up to 17 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety measured by adverse events, physical exams, vital signs, 12-lead electrocardiograms (ECGs) and clinical lab results (including chemistry, hematology, and urinalysis).</measure>
    <time_frame>Up to 17 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>NASH</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>Each subject will receive midazolam on Days 1 and 12.</description>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Caffeine</intervention_name>
    <description>Each subject will receive caffeine on Days 1 and 12.</description>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>Each subject will receive rosuvastatin on Days 2 and 13.</description>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EDP-305</intervention_name>
    <description>Each subject will receive EDP-305 on Days 5 through 15.</description>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  An informed consent document signed and dated by the subject.

          -  Healthy male and female subjects of any ethnic origin between the ages of 18 and 55
             years, inclusive.

          -  Female subjects must be of non-childbearing potential.

        Exclusion Criteria:

          -  Clinically relevant evidence or history of illness or disease.

          -  Pregnant or nursing females.

          -  History of febrile illness within 7 days prior to the first dose of study drug or
             subjects with evidence of active infection.

          -  A positive urine drug screen at screening or Day -1.

          -  Current tobacco smokers or use of tobacco within 3 months prior to screening.

          -  Any condition possibly affecting drug absorption (e.g., gastrectomy, cholecystectomy).

          -  History of regular alcohol consumption.

          -  Participation in a clinical trial within 30 days prior to the first dose of study
             drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Dickerson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pharmaceutical Research Associates</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pharmaceutical Research Associates, Inc.,</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 1, 2017</study_first_submitted>
  <study_first_submitted_qc>June 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 15, 2017</study_first_posted>
  <last_update_submitted>August 16, 2017</last_update_submitted>
  <last_update_submitted_qc>August 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>drug-drug interaction</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Caffeine</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>When the clinical study report has been submitted to the appropriate Regulatory authorities, a lay person summary will be provided to all study subjects by mail or email.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

